Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine + BEAC conditioning vs BEAC alone in peripheral T-cell lymphoma
ChiCTR2000039137Phase 4Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cladribine in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: 2-year progression-free survival after autologous transplantation. Started Oct 2020; status: recruiting.
02
Drugs
cladribine
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2000039137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039137.